Successful treatment of pyoderma gangrenosum with concomitant tofacitinib and infliximab

Martin H. Gregory; Matthew A. Ciorba; Parakkal Deepak; George P. Christophi

doi:10.1093/ibd/izz015

Successful treatment of pyoderma gangrenosum with concomitant tofacitinib and infliximab

Martin H. Gregory, Matthew A. Ciorba, Parakkal Deepak, George P. Christophi

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	E87-E88
Journal	Inflammatory bowel diseases
Volume	25
Issue number	7
DOIs	https://doi.org/10.1093/ibd/izz015
State	Published - Jun 18 2019

Access to Document

10.1093/ibd/izz015

Cite this

@article{e79a4735f44541c1b3edac9b7b0d6894,

title = "Successful treatment of pyoderma gangrenosum with concomitant tofacitinib and infliximab",

author = "Gregory, {Martin H.} and Ciorba, {Matthew A.} and Parakkal Deepak and Christophi, {George P.}",

note = "Funding Information: From the Division of Gastroenterology and Hepatology, Washington University School of Medicine, St. Louis, Missouri Conflict of interest: M.C.: speakers bureau or consulting for UCB, AbbVie, Pfizer, and Takeda; grant support from Incyte, AbbVie, and Takeda. P.D.: received consulting fees from Janssen and Pfizer, speaker fees from Abbvie, and a research grant from Takeda. M.H.G., G.C.: Each of these authors reports no disclosures or conflicts of interest relevant to this study. Funding Information: Supported by: No external funding was used for this project.",

year = "2019",

month = jun,

day = "18",

doi = "10.1093/ibd/izz015",

language = "English",

volume = "25",

pages = "E87--E88",

journal = "Inflammatory bowel diseases",

issn = "1078-0998",

number = "7",

}

TY - JOUR

T1 - Successful treatment of pyoderma gangrenosum with concomitant tofacitinib and infliximab

AU - Gregory, Martin H.

AU - Ciorba, Matthew A.

AU - Deepak, Parakkal

AU - Christophi, George P.

N1 - Funding Information: From the Division of Gastroenterology and Hepatology, Washington University School of Medicine, St. Louis, Missouri Conflict of interest: M.C.: speakers bureau or consulting for UCB, AbbVie, Pfizer, and Takeda; grant support from Incyte, AbbVie, and Takeda. P.D.: received consulting fees from Janssen and Pfizer, speaker fees from Abbvie, and a research grant from Takeda. M.H.G., G.C.: Each of these authors reports no disclosures or conflicts of interest relevant to this study. Funding Information: Supported by: No external funding was used for this project.

PY - 2019/6/18

Y1 - 2019/6/18

UR - http://www.scopus.com/inward/record.url?scp=85068382245&partnerID=8YFLogxK

U2 - 10.1093/ibd/izz015

DO - 10.1093/ibd/izz015

M3 - Letter

C2 - 30753456

AN - SCOPUS:85068382245

SN - 1078-0998

VL - 25

SP - E87-E88

JO - Inflammatory bowel diseases

JF - Inflammatory bowel diseases

IS - 7

ER -

Successful treatment of pyoderma gangrenosum with concomitant tofacitinib and infliximab

Access to Document

Other files and links

Cite this